Prescriptions of chronic disease drugs that Celltrion acquired from Takeda Pharmaceuticals dropped 9% year-on-year in the first half of this year.

Sales of most of the products were already decreasing in the domestic market at the time of Celltrion’s acquisition, and the prolonged COVID-19 crisis contracted the prescription market and further decreased sales of the products.

According to the pharmaceutical market research institution UBIST on the 28th, sales of all the prescription drugs that Celltrion acquired from Takeda Pharmaceutical last year amounted to 33.4 billion won in H1 of this year. This is a 9% drop from the 36.8 billion won earned from prescription drugs in H1 of the pre